V souladu s legislativou České republiky poskytuje Společnost služby pouze kvalifikovaným investorům!

Gracell Biotechnologies Inc. Financial results for the fourth quarter of 2020.

10.03.2021

GAAP net loss - $0.42, which is $0.32 worse compared to the previous year.
Cash and cash equivalents as of December 31, 2020 were $118.5 million.